secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001493152-22-032070
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow Q3 revenue up 22% to $22.8M; FDA approves IHEEZO, narrows net loss
-------------------------------------------------------------------------

- Revenue $22.8M (+22% YoY); net loss narrowed to $6.5M from $8.3M; adjusted EBITDA $2.5M vs. -$0.1M.
- FDA approved IHEEZO (ocular anesthetic NDA) on Sept 27; launch expected to double revenues within 24 months.
- Launched Fortisite (fortified antibiotics) and atropine.com; sold non-ophthalmic product line to become pure-play.
- Core net loss per share ($0.06) improved from ($0.20); revenue per shipping day $355K (+21%).
- Nearly $1M order backlog at quarter end due to supply chain issues; cleared in Q4; scaling production.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315222032070/0001493152-22-032070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315222032070/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-032070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer